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Background. Novel erythropoiesis stimulating protein (NESP)
is a glycoprotein with a threefold longer terminal half-life than
recombinant human erythropoietin (rHuEPO) in humans. The
aim of this study was to determine whether NESP is effective1 In addition to the authors, the European/Australian NESP 980202
for the treatment of anemia at a reduced dosing frequencyStudy Group consists of the following individuals (in alphabetical or-
relative to rHuEPO in patients with chronic renal failure notder): J. Braun (KfH Kuratorium fu¨r Dialyse und Neirentransplantation
e.V., Nu¨rnberg, Germany), Jacques Chanard (Hoˆpital Maison Blanche, yet on dialysis [chronic renal insufficiency (CRI)].
Reims, France), Naomi Clyne (Karolinska Hospital, Stockholm, Swe- Methods. This was a multicenter, randomized, open-label
den), Gerry A. Coles (University Hospital of Wales, Cardiff, Wales, UK), study. A total of 166 rHuEPO-naive patients with CRI were
Jose´ M. Cruz (Hospital Universitario La Fe, Valencia, Spain), Marc randomized in a 3:1 ratio to receive NESP (0.45 g/kg onceDe Broe (UZ Antwerpen, Edegen, Belgium), Angel M. Luis de Fran-
weekly) or rHuEPO (50 U/kg twice weekly) administeredcisco (Hospital de Valdecilla, Santander, Spain), Max Dratwa (Hoˆpital
subcutaneously for up to 24 weeks. Dose adjustments wereUniversitaire Brugmann, Brussels, Belgium), Ram Gokal (Manchester
made as necessary to achieve a hemoglobin response, definedRoyal Infirmary, Manchester, England, UK ), Carola Gro¨nhagen-Riska
(Helsinki University Hospital, Helsinki, Finland), Helmut Graf (Kran- as an increase 1.0 g/dL from baseline and a concentration
kenanstalt Rudolfstiftung, Vienna, Austria), Levi Guerra (Hospital de 11.0 g/dL.
Sa˜o Joa˜o, Porto, Portugal), Thierry Hannedouche (Hospices Civils, Results. During the 24-week treatment period, 93% (95%
Strasbourg, France), David Harris (Westmead Hospital, Westmead, New CI, 87 to 97%) of patients receiving NESP and 92% (95% CI, 78South Wales, Australia), Carmel Hawley (Princess Alexandra Hospital,
to 98%) of patients receiving rHuEPO achieved a hemoglobinWoolloongabba, Queensland, Australia), Herwig Holzer (Medizinische
response. The median time to response was seven weeks (rangeUniversitatklinik Graz, Graz, Austria), Michel Jadoul (UCL St. Luc,
Brussels, Belgium), Peter Kerr (Monash Medical Centre, Clayton, Vic- of 3 to 25 weeks) in both groups. After correction of anemia,
toria, Australia), W. Ko¨sters (Dialyseninstitut, Vielingen-Schwenningen, mean hemoglobin concentrations were maintained within the
Germany), Jean-Louis Lacombe (Clinique Saint-Exupe´ry, Toulouse, target range of 11.0 to 13.0 g/dL for the remainder of the 24-
France), Norbert Lameire (UZ Ghent, Ghent, Belgium), J. Mann week treatment period. The safety profiles of NESP and rHuEPO(Schwabing General Hospital, Munich, Germany), Paolo Marai (Ospe-
were similar, and no antibodies were detected to either drug.dale A. Manzoni, Lecco, Italy), Maria Joao Pais (Hospital de Santa Cruz,
Conclusions. These results demonstrate that NESP safelyCarnaxide, Portugal), Luis Piera (Hospital Universitario Vall D’Hebro´n,
Barcelona, Spain), Pedro Ponce (Hospital Garcia da Orta, Almada, Por- and effectively corrects and maintains hemoglobin concentra-
tugal), E. Quellhorst (Nephrologisches Zentrum Niedersachsen, Hanno- tions at a reduced dosing frequency relative to rHuEPO in
versch-Mu¨nden, Germany), Emilio Rivolta (IRCCS Ospedale Maggiore patients with CRI, providing a potential benefit to patients and
di Milano, Milano, Italy), R.M. Scha¨fer (Medizinische Poliklinik, Mun- health care providers.ster, Germany), G. Stein (Klinikum der Friedrich-Schiller-Universita¨t,
Jena, Germany), Marinus A. van den Dorpel (St. Clara Hospital, Rotter-
dam, The Netherlands), Christopher Winearls (Oxford Renal Unit, Ox-
ford, England, UK), and Carmine Zoccali (Azienda Ospedaliera Bianchi,
Patients with chronic renal failure (CRF) frequentlyMelacrino e Morelli, Reggio Calabria, Italy).
experience anemia, which can significantly affect their
Key words: anemia, novel erythropoiesis stimulating factor, hemoglo- morbidity, mortality, and quality of life. Recombinantbin, recombinant human erythropoietin, red blood cell, and chronic
renal insufficiency. human erythropoietin (rHuEPO) is effective for the treat-
ment of anemia in CRF based on its ability to increase
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However, in most patients, administration is required androgen therapy within eight weeks of the first planned
dose of study drug.two or three times per week.
Previous research on rHuEPO has indicated that its
Study designcarbohydrate content significantly affects its half-life and
biological activity in vivo (abstract; Egrie, Glycoconj J This was a multicenter, randomized, open-label study.
All patients completed a screening period within two10:263, 1993). Novel erythropoiesis stimulating protein
(NESP; ARANESP) is a glycoprotein that was de- weeks before the first dose of study drug. Eligible patients
were then randomized by a centralized system to receivesigned by introducing five amino acid changes into the
primary sequence of rHuEPO to create two extra con- NESP or rHuEPO in a 3:1 ratio, respectively. NESP was
administered subcutaneously at a starting dose of 0.45sensus N-linked glycosylation sites. Consequently, NESP
has five N-linked carbohydrate chains, whereas rHuEPO g/kg once weekly, and rHuEPO was administered sub-
cutaneously at a starting dose of 50 U/kg twice weekly.has only three. The increased carbohydrate content of
NESP results in a terminal half-life in humans that is The dose and frequency of NESP were chosen based on
experience in treating anemia in dialysis patients [5]. Theapproximately threefold longer than that of rHuEPO
after intravenous administration (25.3 hours vs. 8.5 hours, dose of rHuEPO was chosen to approximate the starting
dose of NESP, based on a peptide mass conversion factorrespectively) and at least twofold longer after subcutane-
ous administration (48.8 hours vs. 18 to 24 hours, respec- (1.0 g/kg NESP  200 U/kg rHuEPO), and the fre-
quency of rHuEPO administration was chosen to reflecttively) [3, 4]. This unique pharmacokinetic profile allows
for a reduced dosing frequency, representing a potential the most commonly used frequency at the participating
centers. Study drug dose was adjusted by 25% of theclinical advantage over rHuEPO [5].
Preliminary studies have indicated that NESP, at a starting dose as necessary to achieve a hemoglobin in-
crease of1.0 g/dL from baseline and to maintain hemo-starting dose of 0.45 to 0.75g/kg, is safe and effective for
the treatment of anemia in patients with CRF receiving globin concentrations within a range of 11.0 to 13.0 g/dL.
Additionally, if a patient’s hemoglobin increased by2.0dialysis [5]. However, the effects of NESP have not been
evaluated in patients with CRF not yet on dialysis [chronic g/dL during any four-week period, study drug doses were
reduced by 25% of the starting dose. If a patient’s hemo-renal insufficiency (CRI)]. This multicenter, randomized,
open-label study was designed to evaluate the efficacy globin concentration increased to14.0 g/dL, study drug
was withheld until the hemoglobin concentration felland safety of NESP in this patient population. The
rHuEPO treatment group was included to provide a below 12.0 g/dL and was restarted at a dose 25% lower
than the previous dose. Patients received the first dosereference reflecting current medical practice.
of study drug within seven days of randomization and
continued treatment for 24 weeks. After 24 weeks, pa-
METHODS
tients receiving NESP could continue treatment, and
Patients patients receiving rHuEPO ended the study.
The primary measure of efficacy was the proportionOur study was approved by each institution’s indepen-
dent ethics committee, and all patients gave written in- of patients achieving a hemoglobin response during the
24-week treatment period, defined as an increase in he-formed consent before participation. Patients 18 years
of age or older with a diagnosis of CRI were enrolled moglobin of 1.0 g/dL from baseline and a hemoglobin
concentration of11.0 g/dL. For this assessment, hemo-at 32 dialysis centers in Europe and 4 in Australia. Pa-
tients were not receiving dialysis and were rHuEPO na- globin measurements were taken at two-week intervals
through the end of the 24-week treatment period. Theive (that is, had not received treatment with rHuEPO
within 12 weeks before the first planned dose of study efficacy of NESP was also evaluated by assessing the time
required to achieve a hemoglobin response, hemoglobindrug). Additional entry criteria included a hemoglobin
concentration11.0 g/dL, adequate iron stores (as deter- concentration over time, the dose of study drug at the
time of hemoglobin response and at week 24, and themined by serum ferritin 100 g/L), serum vitamin B12
and folate levels above the lower limit of the normal number of patients receiving red blood cell transfusions.
Measurements to evaluate hemoglobin concentrationrange, and a creatinine clearance of 30 mL/min (as
estimated by the Cockcroft-Gault equation). Exclusion over time were taken at four-week intervals (that is, at
weeks 5, 9, 13, 17, 21, and 25).criteria included uncontrolled hypertension (diastolic
blood pressure 100 mm Hg); congestive heart failure Safety was assessed by monitoring adverse events, lab-
oratory variables (hematology, biochemistry, and iron(New York Heart Association Class III or IV); hemato-
logic disorders that could cause anemia, systemic infec- status), vital signs, and antibody formation to NESP or
rHuEPO. In addition, the ability to increase hemoglobintion or inflammatory disease; or other disorders that
could interfere with the response to NESP or rHuEPO. levels safely was evaluated by the maximum increase in
hemoglobin within any four-week period and the num-Patients had not received a red blood cell transfusion or
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Table 1. Patient demographic and baseline characteristics in novelber of increases in hemoglobin 2.0, 2.5, or 3.0 g/dL
erythropoiesis stimulating protein (NESP)- or recombinant human
within any four-week period. Hematology parameters erythropoietin (rHuEP)-treated patientsa
and vital signs were evaluated every two weeks through-
NESP rHuEPOout the study. Biochemistry parameters and antibody (N  129) (N  37)
formation were evaluated every 12 weeks, and iron status
Sex
was evaluated every four weeks. Men 70 (54%) 19 (51%)
Women 59 (46%) 18 (49%)
RaceStudy medications
Asian 3 (2%) 1 (3%)
Novel erythropoiesis stimulating protein was supplied Black 3 (2%) 0 (0%)
White 123 (95%) 36 (97%)by Amgen Inc. (Thousand Oaks, CA, USA). Recombi-
Age years b 60.4 (15.0) 60.6 (15.7)nant human erythropoietin (Epoetin alfa) was obtained
Primary cause of renal failure
from commercial sources and provided by the pharmacy Diabetes 32 (25%) 8 (22%)
Hypertension 15 (12%) 1 (3%)at each study center. To ensure adequate support of the
Glomerulonephritis 24 (19%) 10 (27%)erythropoietic response to study drug, intravenous iron
Polycystic kidney disease 6 (5%) 2 (5%)
therapy was required to be administered to patients with Other urologic 5 (4%) 0 (0%)
Other 32 (25%) 11 (30%)serum ferritin values 100 g/L. The intravenous iron
Unknown 15 (12%) 5 (14%)dosing regimen used for patients with serum ferritin val-
Hemoglobin g/dLb 9.3 (1.0) 9.8 (1.1)
ues 100 g/L or 100 g/L was determined by the Serum ferritin lg/Lc 168 (30–1420) 151 (31–899)
Creatinine clearance mL/minb 15.7 (6.6) 15.7 (6.4)individual center’s treatment policy.
a Baseline is defined as the closest measurement taken before the first dose
of study drugStatistical analysis
b Mean (SD)
All patients who received at least one dose of the c Median (range)
study drug were included in the analyses of efficacy and
safety. An additional, prospectively defined “per-proto-
col” analysis of efficacy was conducted in those patients
tients receiving NESP or rHuEPO were diabetes mellituswho completed 24 weeks of treatment, had at least 75%
and glomerulonephritis. Hypertension was the mostof the postbaseline hemoglobin measurements, and re-
common medical condition among patients in both theceived within 25% of their total prescribed dose of
NESP and rHuEPO groups at baseline (91 and 84%,study drug, no more than one incorrect dose of study
respectively). The mean baseline hemoglobin concentra-drug, and no red blood cell transfusions before achieving
a hemoglobin response. tion was lower in the NESP group (9.3 g/dL, range of
Descriptive statistics were summarized for all end 6.6 to 11.0) than in the rHuEPO group (9.8 g/dL, range
points according to the treatment group. This study was of 6.1 to 11.5; Table 1). Median baseline serum ferritin
powered to evaluate whether a clinically meaningful pro- levels (168 and 151 g/L in the NESP and rHuEPO
portion of patients receiving NESP achieved a hemoglo- groups, respectively) indicated that most patients were
bin response, which was considered to be 50% of pa- iron replete [6, 7]. Mean creatinine clearance was similar
tients, but was not designed to compare NESP and in the NESP (15.7 mL/min; range of 7 to 44) and rHuEPO
rHuEPO. The sample size of at least 120 NESP patients (15.7 mL/min, range of 4 to 33) groups.
was chosen to give a power of 99% for demonstrating
that the response rate for NESP exceeds 50% (that is, Efficacy
the lower limit of the confidence interval for the NESP A hemoglobin response (defined as an increase of
response rate is 50%).
1.0 g/dL from baseline and a concentration11.0 g/dL)
was achieved by 93% (95% CI, 87 to 97%) of patients
RESULTS receiving NESP during the 24-week treatment period.
Similarly, 92% (95% CI, 78 to 98%) of patients achievedPatient characteristics
a response in the rHuEPO group. These findings werePatients were randomized to receive NESP (129 pa-
supported by the per-protocol analysis, in which 94% oftients) or rHuEPO (37 patients). All 166 patients were
the NESP patients (95% CI, 88 to 98%) and 100% ofincluded in the efficacy and safety analyses. The per-
the rHuEPO patients (95% CI, 88 to 100%) achieved aprotocol analysis set included 105 NESP patients and 29
hemoglobin response. The percentage of patients achiev-rHuEPO patients. Overall, 54% of patients were men,
ing a hemoglobin increase of 1.0 g/dL from baselineand most were white (96%). The mean age was 61 years,
also was comparable between the NESP (99%; 95% CI,with a range of 19 to 87 years. Demographic characteris-
96 to 100%) and rHuEPO (95%; 95% CI, 82 to 99%)tics were similar between the two treatment groups (Ta-
ble 1). The most frequent causes of renal failure in pa- groups. In both treatment groups, the median time to
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Fig. 1. Mean (95% CI) hemoglobin concen-
trations at four-week intervals. The shaded
area indicates target range. Symbols are the pa-
tients receiving: () recombinant human eryth-
ropoietin (rHuEPO); () novel erythropoiesis
stimulating protein (NESP). Abbreviations are:
E, number of patients receiving rHuEPO; N,
number of patients receiving NESP.
achieve a hemoglobin response was seven weeks (range The percentage of patients with dose reductions to levels
below their starting dose up to week 24 was similar inof 3 to 25 weeks).
Mean hemoglobin concentrations increased over the the NESP (68%) and rHuEPO (70%) groups. In patients
who continued to receive NESP after the 24-week treat-initial 12 weeks for patients in both groups and were
maintained within the target range of 11.0 to 13.0 g/dL ment period, the median weekly weight-adjusted dose
at week 48 was 0.30 g/kg (range of 0.1 to 1.7).for the remainder of the 24-week treatment period. In
patients continuing to receive NESP after the 24-week Few patients required a red blood cell transfusion in
the NESP or rHuEPO treatment groups (5 and 8%,treatment period, the mean hemoglobin concentration
remained within the target range for up to 48 weeks respectively). Only three NESP-treated patients and two
rHuEPO-treated patients received a red blood cell trans-(Fig. 1). The difference in hemoglobin levels observed
between the NESP and rHuEPO patients at baseline fusion before achieving a hemoglobin response.
appeared to remain constant throughout the study; thus,
Safetyno difference in the change in hemoglobin from baseline
between the two treatment groups was evident. After The safety profiles of NESP and rHuEPO were similar.
A total of 107 of 129 NESP patients (83%) and 24 of 37the initial four weeks of treatment, the two groups had
comparable increases in mean hemoglobin concentra- rHuEPO patients (65%) experienced at least one ad-
verse event during the study, most of which were mildtions: 1.38 g/dL (95% CI, 1.21 to 1.55) in the NESP group
and 1.40 g/dL (95% CI, 1.07 to 1.72) in the rHuEPO to moderate in severity. The interpretation of differences
between the treatment groups is confounded by thegroup. Mean changes in hemoglobin from baseline were
very similar between the treatment groups up to 24 weeks. open-label design of the study and the potential over-
attribution of adverse events to a novel agent (NESP)Fifty-eight percent of NESP patients and 59% of
rHuEPO patients did not require any dose adjustment compared with an established therapy. Adverse events
occurring in more than 10% of patients in either treat-before achieving a hemoglobin response. A similar per-
centage of patients receiving NESP or rHuEPO had a ment group are presented in Table 2. The most frequently
reported adverse events in the NESP and rHuEPO groupsdose increase (35 and 32%, respectively) or a dose de-
crease (7 and 9%, respectively) before achieving a hemo- were hypertension (32 and 22%, respectively) and pe-
ripheral edema (13 and 11%, respectively). Most of theseglobin response. At the time of hemoglobin response,
the median weekly weight-adjusted dose of NESP was events were attributed to concurrent medical conditions
and were consistent with events expected in this patient0.46 g/kg (range of 0.3 to 2.3 g/kg), and the corre-
sponding dose of rHuEPO was 100 U/kg (range of 75 population. Adverse events that were considered by the
investigator to be treatment related were reported withto 175 U/kg). Both doses were nearly identical to those
at the beginning of the study. At week 24, median study the same frequency in each treatment group (30% NESP
and 27% rHuEPO). Hypertension was the most commondrug doses had decreased to 0.34 g/kg (range of 0.0 to
1.3 g/kg) in patients receiving NESP and to 56.9 U/kg of these events (21% NESP and 19% rHuEPO).
There were six reported deaths (4% NESP and 3%(range of 19 to 250 U/kg) in patients receiving rHuEPO.
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Table 3. Deaths during the study or within 28 days after withdrawalTable 2. Adverse events occurring in 10% of novel erythropoiesis
stimulating protein (NESP)- or recombinant human erythropoietin in novel erythropoiesis stimulating protein (NESP)- or
recombinant human erythropoietin (rHuEPO)-treated patients(rHuEPO)-treated patientsa
NESP rHuEPO Treatment
group Age/sex Study week Primary cause of deathAdverse event (N  129) (N  37)
Hypertension 41 (32%) 8 (22%) rHuEPO 75/M 7 Cardiac arrest
NESP 64/M 16 Cardiac arrestPeripheral edema 17 (13%) 4 (11%)
Fatigue 16 (12%) 0 (0%) NESP 75/F 13a Cachexia
NESP 53/M 10a Multi-organ failureDiarrhea 14 (11%) 3 (8%)
Headache 14 (11%) 4 (11%) NESP 64/M 22 Cardiac arrest
NESP 64/F 23 HematemesisNausea 11 (9%) 5 (14%)
Pruritis 7 (5%) 4 (11%) a Occurred within 28 days after withdrawal from the study
a Data are presented as the number of patients (%) experiencing each adverse
event.
values were 155  19 and 81  11 mm Hg, respectively,
at baseline and 146  20 and 79  12 mm Hg, respec-rHuEPO) during the 24-week treatment period or within
tively, at week 25. In the rHuEPO group, values were28 days after withdrawal from the study (Table 3). The
141  21 and 79  10 mm Hg at baseline and 143  23deaths were largely due to cardiovascular failure and
and 79  8 mm Hg at week 25.occurred in patients with a history of cardiovascular dis-
No clinically meaningful changes in laboratory valuesease.
were evident, and values were similar between the NESPIncreases in hemoglobin were well controlled in pa-
and rHuEPO groups. Mean  SD creatinine clearancetients receiving NESP or rHuEPO. The mean of the
values were 15.7  6.6 mL/min in the NESP group andmaximum increase in hemoglobin over any four-week
15.7  6.4 mL/min in the rHuEPO group at baseline,interval was 1.99 g/dL (95% CI, 1.88 to 2.11) in the
and 14.1  6.7 mL/min and 13.7  7.6 mL/min, respec-
NESP group and 2.13 g/dL (95% CI, 1.88 to 2.39) in
tively, after 24 weeks of treatment. No antibody forma-
the rHuEPO group. The percentage of patients with a
tion to NESP or rHuEPO was detected for any patient
hemoglobin increase of 2.0 g/dL over any four-week
during the study.
interval was 51% in the NESP group and 60% in the
rHuEPO group. In addition, a lower percentage of pa-
DISCUSSIONtients in the NESP group relative to the rHuEPO group
had a hemoglobin increase of 2.5 g/dL (21 and 32%, In patients with chronic renal failure, anemia is associ-
respectively) or3.0 g/dL (9 and 14%, respectively) over ated with an increased risk of cardiovascular morbidity
any four-week period. In patients who had study drug and mortality and a reduction in quality of life. Correc-
withheld for hemoglobin concentrations 14.0 g/dL tion of hemoglobin and hematocrit levels has been shown
(24% NESP and 35% rHuEPO), the median time re- to reduce cardiovascular risk factors such as left ventricu-
quired for hemoglobin levels to return to 12.0 g/dL lar hypertrophy and improve energy and physical func-
was similar in the NESP (7 weeks, range of 2 to 13) and tioning, emphasizing the importance of treating anemia
rHuEPO (9 weeks, range of 6 to 13) groups (Fig. 2). in this population [2, 8, 9].
After four weeks of treatment, median serum ferritin This is the first report of the administration of NESP
concentrations had decreased in the NESP and rHuEPO to patients with CRI. The results of this study demon-
groups from baseline values of 168 and 151 g/L to 80 strate that NESP, administered once weekly at a starting
and 63 g/L, respectively. Median serum ferritin concen- dose of 0.45 g/kg, is safe and effective for the correction
trations remained100 g/L until week 17, when values of anemia and maintenance of hemoglobin concentrations
increased to 108 and 101 g/L in the NESP and rHuEPO in this patient population. Of the 129 patients random-
groups, respectively. Median concentrations remained ized to receive NESP, 93% achieved a hemoglobin re-
above 100 g/L for the rest of the 24-week treatment sponse during the 24-week treatment period. Although
period. Intravenous iron was administered to 77% of hemoglobin concentrations were lower in the NESP
patients receiving NESP and 81% of patients receiving group than in the rHuEPO group at baseline, both the
rHuEPO, at a total mean patient dose of 685 mg and proportion of patients achieving a hemoglobin response
678 mg, respectively. In addition, oral iron was adminis- and the time to achieve this response were the same
tered to a similar proportion of patients in the NESP for patients receiving NESP once weekly or rHuEPO
(52%) and rHuEPO (51%) groups. administered twice weekly. The degree of anemia correc-
Vital signs were stable during the 24-week treatment tion with NESP treatment was also similar to that ob-
period in both treatment groups. In patients receiving served in previous studies of rHuEPO administered
three times weekly in patients with CRI [10–12].NESP, mean  SD systolic and diastolic blood pressure
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Fig. 2. Time required for hemoglobin concen-
trations to return to 12.0 g/dL after withheld
doses for hemoglobin concentrations 14.0
g/dL. Symbols are: () rHuEPO (N  13);
() NESP (N  31). Means and 95% CIs are
shown.
Consistent with previous observations of NESP ad- laboratory or vital sign measures, and changes in mean
creatinine clearance were similar between treatmentministered intravenously or SC in patients with CRF re-
ceiving dialysis [5], a NESP starting dose of 0.45 g/kg/ groups.
The correction of anemia with NESP treatment wasweek was effective for the correction of anemia in the
CRI population. The median dose of NESP at the time well controlled, with mean hemoglobin concentrations
maintained within the target range of 11.0 to 13.0 g/dLpatients achieved the target hemoglobin range was simi-
lar to the starting dose. However, the median NESP dose for up to 48 weeks. During the initial 24-week treatment
phase, increases in hemoglobin over any four-week pe-was reduced to 0.34 g/kg after 24 weeks of treatment,
potentially reflecting titration to maintain hemoglobin riod were 2.5 g/dL in most patients, consistent with
current recommendations for the management of anemiawithin the target range. Reduced maintenance doses
were also observed for patients receiving rHuEPO in in CRI [6, 7]. In patients who had doses withheld for
hemoglobin concentrations14.0 g/dL during the study,this study and have been reported in other studies of
patients with CRF receiving rHuEPO [1, 13]. the time required for levels to return to 12.0 g/dL was
similar in the NESP and rHuEPO treatment groups. ThisAdverse events were consistent with those expected
in a population of patients with CRI and were generally result suggests that the rate of decline in hemoglobin
after withholding NESP or rHuEPO therapy is primarilyconsidered unrelated to the study drug. While a higher
overall incidence of adverse events was reported for the determined by destruction of circulating red blood cells
as they reach the end of their lifespan, and not by clear-NESP group than for the rHuEPO group, this difference
may have been a consequence of the open-label design ance of the study drug.
Median serum ferritin concentrations in both treat-of the study and the potential over-attribution of adverse
events to a novel agent compared to an established therapy. ment groups decreased below the recommended level
of 100 g/L [6, 7] during the initial correction of anemiaThe 3:1 randomization of patients to NESP or rHuEPO
and the resulting small number of patients evaluated and subsequently increased following supplemental in-
travenous iron therapy. Other studies in patients within the rHuEPO group may have also contributed to the
observed difference. Patients in the NESP group had lower CRI receiving rHuEPO therapy have also reported a
high incidence of absolute or functional iron deficiencybaseline hemoglobin, a higher incidence of hypertension
at baseline (91% NESP and 84% rHuEPO), and higher requiring intravenous or oral supplementation [10, 11,
14]. As iron deficiency is the most common cause ofbaseline systolic blood pressure values (155 mm Hg
NESP and 141 mm Hg rHuEPO). These results suggest resistance to rHuEPO therapy, iron stores should be
monitored regularly in patients receiving NESP to en-that the NESP group had a greater burden of comorbid-
ity and may partially explain the difference in adverse sure adequate support of the erythropoietic response.
Further research into optimal iron supplementation inevents between treatment groups, particularly since hy-
pertension was the most common adverse event reported this population is warranted.
Although rHuEPO most commonly is administeredin this study.
No clinically significant changes were observed for any two or three times weekly for the treatment of anemia
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ease: Results of a phase III multicenter clinical trial. Ann Internin CRF, it has also been used once weekly in some
Med 111:992–1000, 1989
patients. As a result of the extended half-life of NESP 2. Revicki DA, Brown RE, Feeny DH, et al: Health-related quality
of life associated with recombinant human erythropoietin therapyrelative to rHuEPO, even longer dosing intervals are
for predialysis chronic renal disease patients. Am J Kidney Dispossible with NESP therapy [3]. In a randomized, com-
25:548–554, 1995
parative study of NESP and rHuEPO in dialysis patients, 3. Macdougall IC, Gray SJ, Elston O, et al: Pharmacokinetics of
novel erythropoiesis stimulating protein compared with Epoetin95% of patients who were receiving rHuEPO once
alfa in dialysis patients. J Am Soc Nephrol 10:2392–2395, 1999weekly at baseline successfully maintained stable hemo-
4. Macdougall IC, Roberts DE, Coles GA, Williams JD: Clinical
globin concentrations when switched to NESP adminis- pharmacokinetics of Epoetin (recombinant human erythropoie-
tin). Clin Pharmacokinet 20:99–113, 1991tered once every two weeks [5]. The longer dosing interval
5. Macdougall IC: Novel erythropoiesis stimulating protein. Seminwith NESP offers the possibility of greater convenience Nephrol 20:375–381, 2000
and less patient discomfort by reducing the number of 6. NKF-DOQI clinical practice guidelines for the treatment of anemia
of chronic renal failure. Am J Kidney Dis 30(Suppl):S192–S240,physician office visits (where standard practice) and sub-
1997cutaneous injections. With dose administration once 7. Working Party for European Best Practice Guidelines for
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